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Sir, 
 
We have with great interest read the paper by Ng and colleagues, recently published in the 
Journal of Clinical Neuroscience.1 Authors have reported a case of a young female patient 
who initially experienced an episode of neurological symptoms caused by histologically 
proven demyelinating lesion, and who after four years of remission developed primary central 
nervous system lymphoma (PCNSL). The conclusion was made that demyelinating lesions of 
the central nervous system (CNS) may precede development of PCNLS for more than four 
years.  
We agree with the authors’ statement that PCNSL should be considered in patients presenting 
with space-occupying lesions even if the histology shows classical perivascular cuffing of 
small lymphocytes and extensive myelin destruction. However we think that this connection 
in this particular patient is not fully explored. 
First, demyelinating lesions of the central nervous system can be caused by many diseases, 
other than multiple sclerosis.2,3 The initial evaluation of these patients should include CSF 
examination looking for cell counts, atypical lymphoma cells, oligoclonal bands, serology for 
Borrelia, immunological tests like ANA, cardiolipin antibodies or SS-A and SS-B antibodies, 
and visual evoked potentials to look for demyelination of the optic nerve. As well history data 
of preceding viral illness or thick byte can be very useful. This is of special importance 
because all these diseases, like acute disseminated encephalomyelitis or neuroborreliosis can 
give similar findings on biopsy specimen pathology findings. We think that adding all this 
data to the first clinical presentation of reported patient can greatly help in evaluation of the 
first lesion. Another important fact is the lesion location. Although possible, basal ganglia 
demyelination is rare, and this is a typical location for the PCNSL.4 As well, initial MRI is not 
typical neither for tumefactive MS plack, neither for Balo’s concentric sclerosis.5 The nodular 
type of post Gadolinium enhancement is more suggestive of tumor etiology. 
Second important fact is that corticosteroid treatment was given before the initial biopsy was 
performed. It is well known that corticosteroid treatment can mask clinical, CT or MRI 
appearance of PCNSL, and this is also true for the histopathological findings. Another 
question is was the specimen taken by stereotactic biopsy from the tissue surrounding the 
PCNSL or from the PCNSL itself. These are all factors that can make histopathological 
examination very difficult to interpret.  
Third, although authors acknowledge the possibility that the initial lesion was the case of 
steroid-treated PCNSL, this is not fully explored. There are several, well documented 
literature reports of spontaneous remission of PCNSL. In some of these cases the remission 
was more than three years, it was not influenced with corticosteroid therapy, and the recurrent 
tumor was on the different location than the previous one.6,7 The possible explanation for the 
this is that some kind of immune trigger leads to an increased ration of the natural killer cells 
to lymphoma cells and thus causes remission.6 Another interesting phenomena is an 
observation that many remissions, especially in Burkitt’s lymphoma are triggered by incision 
biopsy.8 This is a possibility in the reported patient, as the initial lesion was diagnosed with 
stereotactic biopsy.  
Finally, Epstein-Barr virus (EBV) infection is implicated in the pathogenesis of PCNSL4, 
systemic lymphoma9 and multiple sclerosis10 (representing the most frequent demyelinating 
disease of the CNS). Our group has recently described a patient with Hodgkin’s lymphoma, 
who subsequently developed MS.11 This association is particularly interesting because EBV is 
implicated in the pathogenesis of lymphomas and it is considered one of the triggers for 
development of MS. It would be interesting to explore this association on the patient 
presented by the authors, especially EBV seropositivity in the initial stages of the disease.  
To conclude, although sentinel demyelination has occasionally been reported in patients with 
PCNSL, there is no convincing evidence to suggest that this is a true association or just 
previously unrecognized cases of PCNSL. 
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